Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT?
iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.
Both iShares' Pharma ETF IHE and First Trust's Biotech Fund FBT provide specialized exposure to different sub-industries within the healthcare sector. However, they cater to distinct investment strategies.
IHE, with its lower expense ratio of 0.37%, offers broad exposure to domestic drugmakers through its 53 holdings. This makes it a more cost-effective choice for long-term investors, with a focus on stability and steady cash flows. Its largest positions include Eli Lilly and Johnson & Johnson, which account for a significant portion of its portfolio.
On the other hand, FBT provides concentrated exposure to the high-growth biotech space. It holds exactly 30 securities within the healthcare sector, employing an equal-weighted methodology to reduce concentration in any single name. While FBT has outperformed IHE over the past decade, it carries a higher level of volatility due to its focused nature and lack of dividend payments.
Ultimately, the choice between IHE and FBT depends on the investor's risk tolerance and investment horizon. For those seeking a more stable, long-term strategy with lower fees, IHE may be the better buy. However, investors willing to accept higher volatility in pursuit of potentially higher growth may find FBT more appealing.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.